Formerly known as Sialix Inc, and before that as GC-Free Inc., having facilites in Newton MA and in San Diego CA. Siamab Therapeutics is a biopharmaceutical company structured around a technology platform that enables the discovery of highly specific anti-TACA therapeutic antibodies. The firm's pipeline includes ST1, a program that targets a tumor associated carbohydrate antigen present in various solid tumors, including ovarian, prostate, pancreatic, gastric, and colon. These highly cancer specific, tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric, and breast, and are exploited by tumor cells to suppress innate immune function. In addition, the company has developed a platform of technologies that enable the rapid discovery and development of therapeutic antibodies. The companyâs technology was licensed from glycobiology researcher Ajit Varki of University of California, San Diego
